# 2025-22763: DEA Bans Designer Xanax Knockoff With Ridiculous Name

2025-22763, Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I, is a Federal Register proposed rule from Justice Department, Drug Enforcement Administration published 2025-12-15, effective 2025-12-15 (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-22763
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-22763
- Title: Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
- Type: Proposed Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 57924
- Published: 2025-12-15
- Effective: 2025-12-15
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Bans Designer Xanax Knockoff With Ridiculous Name

## Summary

Starting December 15, 2025, bromazolam—a drug similar to some strong sedatives—will be temporarily placed in Schedule I, meaning it’s considered very risky and illegal to make, sell, or use without special permission. This affects anyone who handles bromazolam, including makers, sellers, researchers, and users, who will now face strict rules and penalties. The move aims to keep people safe by controlling this drug quickly while the government studies it more.

## Abstract

The Administrator of the Drug Enforcement Administration is issuing this notification of intent to publish a temporary order to schedule 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][l, 4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. When it is issued, the temporary scheduling order will impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle bromazolam.

## Effects PRIA read

- Bromazolam moved to Schedule I: cost, high. The Drug Enforcement Administration intends to temporarily place bromazolam in Schedule I. When the temporary order is published, persons who handle bromazolam — including manufacture, distribution, import, export, or possession — will be subject to the regulatory controls and administrative, civil…
- Researchers and labs face Schedule I rules: cost, medium. Researchers, laboratories, and instructors who engage in research, instructional activities, or chemical analysis of bromazolam will be subject to Schedule I regulatory controls and the same administrative, civil, and criminal sanctions. This change takes effect when the temporary scheduling order…
- Temporary listing lasts two years (±1 year): cost, medium. The temporary Schedule I placement will take effect on the date the temporary scheduling order is published in the Federal Register (the order will not be issued before January 14, 2026). The temporary placement will remain in effect for two years and may be extended for one additional year if regu…
- Temporary orders not subject to judicial review: cost, low. Temporary scheduling orders under 21 U.S.C. 811(h) are not subject to judicial review. That means affected parties cannot immediately seek court review of the temporary placement of bromazolam while the order is in effect.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-22763 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/15/2025-22763/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i)
- [2025-22763 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-15/pdf/2025-22763.pdf)

## Related
- [Previous: 2025-22756, Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or…](https://policyrisk.com/federal-register/2025-22756)
- [Next: 2025-22775, Income of Foreign Governments and of International Organizations](https://policyrisk.com/federal-register/2025-22775)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-22763 (as of 2026-06-11).
